SCHEMBL24252272

SCHEMBL24252272

COc1ccc(B2OC(C)(C)C(C)(C)O2)cc1-c1ccc2c(N)nnc(C)c2c1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.40
DHFR P00374 4/20 0.37
SNCA P37840 1/20 0.35
PDGFRB P09619 2/20 0.34
KDR P35968 2/20 0.34
LPL P06858 6/20 0.34
LIPG Q9Y5X9 6/20 0.34
MAP4K4 O95819 1/20 0.34
BACE1 P56817 3/20 0.32
APP P05067 2/20 0.32
ALDH1A1 P00352 1/20 0.31
CYP3A4 P08684 1/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL30467592 0.91 F2 (0.40) CSF1RDHFRPDGFRBKDRLPL
SCHEMBL24252793 0.86 PDGFRB (0.32) PDGFRBKDR
SCHEMBL25235915 0.86 PDGFRB (0.32) CSF1RPDGFRBKDR
SCHEMBL24252330 0.84 DHFR (0.32) CSF1RDHFRMAP4K4ALDH1A1CYP3A4
SCHEMBL24252886 0.84 PDGFRB (0.34) CSF1RSNCAPDGFRBKDRLPL
SCHEMBL24252626 0.82 DHFR (0.39) CSF1RDHFRSNCAPDGFRBKDR
SCHEMBL24252692 0.81 DHFR (0.42) CSF1RDHFRSNCAPDGFRBKDR
SCHEMBL24252781 0.79 SCN9A (0.33)
Trifluoroacetic Acid SCHEMBL30467727 0.79 F2 (0.35) PDGFRBKDRLIPG
Trifluoroacetic Acid SCHEMBL30467711 0.79 F2 (0.35) PDGFRBKDRLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 CSF1R 963/4885DHFR 1380/4885SNCA 759/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 CSF1R 963/4885DHFR 1380/4885SNCA 759/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 CSF1R 963/4885DHFR 1380/4885SNCA 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.